Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Malignant Neoplasms
|
1641 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.080 | 1.000 | 8 | 2012 | 2020 | |||||
Primary malignant neoplasm
|
1374 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.080 | 1.000 | 8 | 2012 | 2020 | |||||
Breast Carcinoma
|
2793 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.020 | 1.000 | 2 | 2018 | 2019 | |||||
Malignant neoplasm of breast
|
3417 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.020 | 1.000 | 2 | 2018 | 2019 | |||||
Malignant neoplasm of urinary bladder
|
316 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.020 | 1.000 | 2 | 2013 | 2014 | |||||
Acute leukemia
|
50 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Acute pancreatitis
|
51 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Bladder Neoplasm
|
281 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Carcinoma of bladder
|
309 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Colon Carcinoma
|
275 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Colorectal Carcinoma
|
1962 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Endometrial Carcinoma
|
326 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Liver carcinoma
|
942 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Malignant neoplasm of colon and/or rectum
|
502 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Malignant neoplasm of endometrium
|
197 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Malignant neoplasm of pancreas
|
277 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Malignant tumor of colon
|
688 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Neoplasms
|
1644 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Pancreatic carcinoma
|
322 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Progression of prostate cancer
|
7 | 0.695 | 0.280 | 17 | 78214286 | 5 prime UTR variant | G/A;C;T | snv | 0.38; 4.8E-06 | 0.010 | 1.000 | 1 | 2013 | 2013 |